NASDAQ · IRMD
Healthcare · Medical - Devices
$82.41
Up+$0.56 (+0.68%)
Updated Sep 16, 2026, 4:04 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
IRMD closed at $82.41 after 20 trading sessions, down 5.87% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $82.23 | $83.23 | $81.50 | $82.41 | 95.96K |
| Sep 14, 2026 | $82.93 | $84.055 | $82.17 | $82.53 | 90.16K |
| Sep 11, 2026 | $82.99 | $83.89 | $81.62 | $82.22 | 285.63K |
| Sep 10, 2026 | $83.08 | $83.20 | $81.405 | $81.87 | 120.2K |
| Sep 9, 2026 | $83.62 | $85.11 | $83.155 | $83.56 | 74.73K |
| Sep 8, 2026 | $83.31 | $86.77 | $83.20 | $84.40 | 105.48K |
| Sep 4, 2026 | $85.96 | $86.5903 | $83.275 | $83.45 | 233.29K |
| Sep 3, 2026 | $87.15 | $87.28 | $85.89 | $86.59 | 73.22K |
| Sep 2, 2026 | $86.89 | $88.26 | $85.90 | $86.17 | 96.03K |
| Sep 1, 2026 | $86.26 | $87.67 | $86.06 | $86.38 | 68.44K |
| Aug 31, 2026 | $86.57 | $86.8578 | $85.25 | $86.38 | 113.02K |
| Aug 28, 2026 | $87.16 | $88.395 | $86.43 | $87.07 | 49.73K |
| Aug 27, 2026 | $87.00 | $88.385 | $86.39 | $87.00 | 76.2K |
| Aug 26, 2026 | $88.20 | $88.88 | $87.125 | $87.47 | 87.7K |
| Aug 25, 2026 | $87.29 | $89.13 | $85.735 | $87.87 | 88.01K |
| Aug 24, 2026 | $88.14 | $88.44 | $86.73 | $87.18 | 82.52K |
| Aug 21, 2026 | $86.83 | $87.95 | $86.335 | $87.85 | 76.18K |
| Aug 20, 2026 | $86.93 | $88.5206 | $86.596 | $86.68 | 80.01K |
| Aug 19, 2026 | $87.88 | $89.03 | $87.135 | $87.40 | 100.86K |
| Aug 18, 2026 | $88.76 | $88.83 | $86.865 | $87.55 | 66.9K |
The latest Smart Investors Daily articles mentioning IRMD.
IRMD research
Company profile and research snapshot.
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 14, 2025 | Roth MKM | Buy | — |
| Aug 2, 2024 | Roth MKM | Buy | — |
| Apr 22, 2024 | Roth MKM | Buy | — |
| Aug 2, 2021 | Roth Capital | Buy | — |
| Jul 31, 2017 | Roth Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 4, 2026
iRadimed Corp (IRMD) navigates a pivotal transition quarter with robust bookings for its next-generation MRI pump, offset by near-term margin pressure and flat revenue growth.
Yahoo · Jul 31, 2026
iRadimed (NASDAQ:IRMD) reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp. GAAP net income was $5.2 million,
ChartMill · Jul 31, 2026
IRADIMED (IRMD) beat Q2 EPS, revenue in line; reaffirms full-year guidance. Stock rises premarket as 3870 pump transition stays on track.
SeekingAlpha · Jul 31, 2026
IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call July 31, 2026 11:00 AM EDTCompany ParticipantsRoger Susi - Founder, Chairman, CEO & PresidentJohn...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IRMD.
